Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:12:51 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Z:RDY - DR REDDYS LABORATORIES ADS EACH REPR 1 ORD INR5 - https://www.drreddys.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RDY - Z0.112.26·14.300.514.08+0.1250.92,900.939,70410,03514.14  14.14  13.8416.16  12.283519:25:39Jan 1415 min RT 2¢

Recent Trades - Last 10 of 10035
Time ETExPriceChangeVolume
19:25:39Z14.290.325
19:11:10Z14.160.1923
19:04:39Z14.150.182
18:35:35Z14.150.18145
16:11:06Z13.85-0.128
16:10:04Z14.080.111
16:10:04Z14.080.111
16:10:04Z14.080.111
16:10:04Z14.080.111
16:04:46Z14.080.111

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-14 08:49U:RDYNews ReleaseDr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday(TM) Once Daily Relief, in the U.S.
2025-12-02 08:00U:RDYNews ReleaseAurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
2025-10-22 12:00U:RDYNews ReleaseAurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
2025-08-25 08:00U:RDYNews ReleaseCoya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
2025-07-23 13:46U:RDYNews ReleaseDr. Reddy's Q1FY26 Financial Results
2025-06-05 07:00U:RDYNews ReleaseAlvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda(TM) (pembrolizumab)
2025-05-09 14:53U:RDYNews ReleaseDr. Reddy's Q4 & Full Year FY25 Financial Results
2025-03-27 11:47U:RDYNews ReleaseBio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara(TM) Biosimilar, and BAT2506, a Proposed Simponi(TM) Biosimilar, for Southeast Asia
2025-03-18 08:35U:RDYNews ReleaseAlvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia(TM) and Xgeva(TM)
2025-03-13 10:40U:RDYNews ReleaseDr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag